Autoimmune Connective Tissue and Bullous Disease
In this medfyle
Expert commentary by Martina Lambertini, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AAD Virtual Meeting Experience and presented by:
Victoria P. Werth, MD
University of Pennsylvania and Philadelphia VA Medical Center, Philadelphi, PA, USA
The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Synthesis Editorial Ltd, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Hassan Galadari, MD, FAAD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Martina Lambertini, MD
Policlinico S.Orsola-Malpighi
Bologna, Italy
About the Expert
Martina Lambertini, MD
Policlinico S.Orsola-Malpighi
Bologna, Italy
Martina Lambertini, MD, is a board-certified dermatologist and a research fellow at the University of Bologna, Italy.
References
1. Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide Therapy in Treatment-Refractory Cutaneous Lupus Erythematosus: Histologic and Circulating Leukocyte Profile and Potential Risk of a Systemic Lupus Flare. J Am Acad Dermatol 2012;66:571–82.
2. Cortes-Hernadez J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and Safety of Lenalidomide for Refractory Cutaneous Lupus Erythematosus. Arth Res & Ther 2012;14:R265.
3. Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus. J Clin Rheumatol 2011;17:142–4.
4. Vital EM, Wittman M, Edward S, et al. Brief Report: Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus. Arthritis Rheumatol 2015;67:1586–91.
5. Manzi S, Sánchez-Guerro J, Merrill JT, et al. Effects of Belimumab, a B Lymphocyte Stimulator-Specific Inhibitor, on Disease Activity Across Multiple Organ Domains in Patients With Systemic Lupus Erythematosus: Combined Results From Two Phase III Trials. Ann Rheum Dis 2012;71:1833–88.
6. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol 2017;69:2271–82.
7. Da Silva D, Patel P, Werth VP. Dermatomyositis: A Diagnostic Dilemma. J Am Acad Dermatol 79;371–73.
8. Leandro MJ. B-cell Subpopulations in Humans and Their Differential Susceptibility to Depletion With anti-CD20 Monoclonal Antibodies. Arth Res Ther 2013;15(suppl 1):S3.
9. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line Rituximab Combined With Short-Term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial. Lancet 2017;389:2031–40.
10. Werth VP, et al. Presented at EADV 2019.
11. Amagai M, Ikeda S, Shimizu H, et al. A Randomized Double-Blind Trial of Intravenous Immunoglobulin for Pemphigus. J Am Acad Dermaol 2009;60:595–603.
